Xilio Therapeutics, Inc.

XLO

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001840233

SEC filings (opens in a new tab)

No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Xilio Therapeutics, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023 All holders in Q1 2023

13F holders of XLO: Q1 2023 compared with Q2 2023
Measure	Q1 2023	Q2 2023	Change
Holders	32	32	0
Shares	16.1M	16.0M	−69.8K (−0.4%)
Value	$51.0M	$41.9M	−$9.05M (−17.8%)

New holders (1)

Institutions that held Xilio Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to XLO in Q2 2023
Institution	Shares	Value	% of portfolio
Charles Schwab Investment Management Inc	11,925	$31.2K	0.00%

Sold out (1)

Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of XLO in Q2 2023
Institution	Shares, Q1 2023	Value, Q1 2023
Cannell Capital LLC	17,025	$54.0K